CS
ALXN

Comerica Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Comerica Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,872
Closed -$895K – 504
2021
Q2 		$895K Sell
4,872
-2,814
-37% -$483K 0.07% 234
2021
Q1 		$1.18M Sell
7,686
-6,107
-44% -$945K 0.09% 192
2020
Q4 		$2.15M Buy
13,793
+1,702
+14% +$219K 0.17% 118
2020
Q3 		$1.38M Sell
12,091
-1,974
-14% -$213K 0.12% 147
2020
Q2 		$1.58M Buy
14,065
+1,080
+8% +$115K 0.15% 134
2020
Q1 		$1.17M Buy
12,985
+719
+6% +$70.6K 0.13% 149
2019
Q4 		$1.33M Buy
12,266
+290
+2% +$31K 0.13% 167
2019
Q3 		$1.17M Buy
11,976
+1,513
+14% +$171K 0.12% 168
2019
Q2 		$1.37M Buy
10,463
+3,993
+62% +$515K 0.15% 149
2019
Q1 		$875K Buy
6,470
+2,430
+60% +$302K 0.1% 204
2018
Q4 		$393K Sell
4,040
-950
-19% -$112K 0.05% 283
2018
Q3 		$694K Buy
4,990
+375
+8% +$47K 0.08% 234
2018
Q2 		$573K Buy
4,615
+355
+8% +$41.5K 0.07% 250
2018
Q1 		$475K Buy
4,260
+1,015
+31% +$121K 0.06% 275
2017
Q4 		$388K Buy
3,245
+189
+6% +$23K 0.05% 298
2017
Q3 		$429K Buy
3,056
+662
+28% +$89.9K 0.06% 274
2017
Q2 		$291K Buy
2,394
+196
+9% +$22.8K 0.04% 325
2017
Q1 		$266K Buy
+2,198
New +$283K 0.04% 333
2015
Q3 		– Sell
-2,396
Closed -$433K – 349
2015
Q2 		$433K Buy
+2,396
New +$413K 0.11% 208

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Comerica Securities's ALXN Position: Q3 2021 in Review

Comerica Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,872 shares — an estimated $895K sold.

Comerica Securities first reported a position in ALXN in Q2 2015 and held it in 19 quarters. The position peaked at $2.15M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Comerica Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Comerica Securities sold 4,872 Alexion Pharmaceuticals shares in Q3 2021, an estimated $895K.
  • Comerica Securities first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 19 quarters.
  • Comerica Securities's Alexion Pharmaceuticals position peaked at $2.15M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Comerica Securities's 13F filing for Q3 2021, filed 10 Nov 2021.